Antithrombin Cambridge ll (A384S) supports a role for antithrombin deficiency in arterial thrombosis

Thrombosis and Haemostasis

Volumn 101, Issue 3, 2009, Pages 483-486

  Roldán, Vanessa ^a   Ordonez, Adriana ^a   Marin, Francisco ^b   Zorio, Esther ^c   Soria, José M ^d   Miñano, Antonia ^a   España, Francisco ^c   Rocio, González Conejero ^a   Pineda, Javier ^e   Estellés, Amparo ^c   Fontcuberta, Jordi ^d   Vicente, Vicente ^a   Corral, Javier ^a,f  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

Author keywords

Anticoagulants; Genetics; Myocardial infarction; Risk factors; Thrombosis

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN CAMBRIDGE II; UNCLASSIFIED DRUG; ANTITHROMBIN III;

ADULT; AGE DISTRIBUTION; ANTITHROMBIN DEFICIENCY; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVOR; AGE; AGED; ANTITHROMBIN III DEFICIENCY; CAUCASIAN; CORONARY ARTERY THROMBOSIS; GENETICS; MIDDLE AGED; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; CORONARY THROMBOSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SEX FACTORS;

EID: 62549106201     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-9-0583     Document Type: Article

References (30)

1. de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44: 106-113.
2. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
3. Casas JP, Hingorani AD, Bautista LE, et al. Metaanalysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004; 61: 1652-1661.
4. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
5. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000: 106: 873-878.
6. Franco RF, Reitsma PH. Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol 2001; 115: 491-506.
7. Conard J, Samama MM. Inhibitors of coagulation, atherosclerosis, and arterial thrombosis. Semin Thromb Hemost 1986; 12: 87-90.
8. Coller BS, Owen J, Jesty J, et al. Deficiency of plasma protein S. protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis 1987; 7: 456-462.
9. Chowdhury V, Lane DA, Mille B, et al. Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198-202.
10. Brown S A, Mitchell M, Cutler JA, et al. Rapid genetic diagnosis in neonatal pulmonary artery thrombosis caused by homozygous antithrombin Budapest 3. Clin Appl Thromb Hemost 2000; 6: 181-183.
11. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
12. Corral J, Hemandez-Espmosa D, Soria JM, et al., Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
13. Giacomelli SH, Simioni M, Madeo D, et al. Antithrombin deficiency in the general population is rarely due to AT gene mutations, which are mainly represented by Ala384Ser mutation. J Thromb Haemost 2007; 5 (Suppl 2): P-M-467.
14. Perry DJ, Daly ME, Tait RC, et al. Antithrombin Cambridge II (Ala384Ser): clinical, functional and ha-plotype analysis of 18 families. Thromb Haemost 1998; 79: 249-253.
15. Barba P, Santamaría A, Tirado I, et al. Antithrombin Cambridge II mutation as a risk factor to develop cerebral venous thrombosis. Thromb Haemost 2008; 99: 443-444.
16. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined. A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513.
17. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
18. Pathak A, Zhao R, Monroe DM, Roberts et al. Thrombin generation in vascular tissue. J Thromb Haemost 2006; 4: 60-67.
19. Andreotti F, Testa L, Biondi-ZoccaiGGL, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: anupdated and comprehensive meta-analysis of 25307 patients. Eur Heart J 2006; 27: 519-526.
20. Husmann M, Barton M. Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. Expert Opin Investig Drags 2007; 16: 563-567.
21. He L, Vicente CP. Westrick RJ, et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-219.
22. Aihara K, Azuma H, Akaike M, et al.. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-delicient mice. J Clin Invest 2007; 117: 1514-1526.
23. de Agostini AI, Watkins SC, Slayter HS, et al. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol 1990; 111: 1293-1304.
24. McCoy AJ, Pel XY, Skinner R, et al. Structure of bcta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. J Mol Biol 2003; 326: 823-833.
25. Frebelius S, Isaksson S, Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT?. Arterioscler Thromb Vasc Biol 1996; 16: 1292-1297.
26. Witmer MR, Hatton MW. Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelized aortic wall in vitro and in vivo. Arterioscler Thromb 1991; 11: 530-539.
27. Leng B, Lu A, Riesenfeld J, et al. Enhanced heparin binding affinities increase the efficiencies at which the beta-antithrombin III isoform and a recombinant ATIII variant load onto pentasaccharide-bearing surfaces under flow. J Thromb Haemost 2007; 5 (Suppl 2): P-W-053.
28. Williams MJ, Restieaux NJ, Low CJS. Myocardial infarction in young people with normal coronary arteries. Heart 1998; 79: 191 -194.
29. Mushunje A, Zhou A, Carrell RW, et al. Heparin-induced substrate behaviour of antithrombin Cambridge II. Blood 2003; 102: 4028-4034.
30. D'hondt C. Role for heparan sulfate proteoglycan in thrombin-induced calcium transients and nitric oxide production in aortic endothelial cells. Thromb Haemost 2008; 100: 374-376.